A large-animal study reported that an engineered “living medicine” based on Mycoplasma pneumoniae reduced antibiotic-resistant Pseudomonas aeruginosa biofilm thickness on ventilator tubes after nebulized delivery in pigs. Investigators reported a measurable reduction in biofilm thickness of about 40% without evidence of tissue damage and without detectable disruption of native airway microbiota. The work is notable for moving a biofilm-targeting therapeutic from rodent demonstrations into a respiratory-size model closer to human clinical conditions.